Structural and Functional Basis of JAMM Deubiquitinating Enzymes in Disease

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2022 Jul 27

PMID 35883466

Authors

Xin Pan

Sihua Wu

Wenping Wei

Zixuan Chen

Yong Wu

Kaizheng Gong

Affiliations

Soon will be listed here.

Abstract

Deubiquitinating enzymes (DUBs) are a group of proteases that are important for maintaining cell homeostasis by regulating the balance between ubiquitination and deubiquitination. As the only known metalloproteinase family of DUBs, JAB1/MPN/Mov34 metalloenzymes (JAMMs) are specifically associated with tumorigenesis and immunological and inflammatory diseases at multiple levels. The far smaller numbers and distinct catalytic mechanism of JAMMs render them attractive drug targets. Currently, several JAMM inhibitors have been successfully developed and have shown promising therapeutic efficacy. To gain greater insight into JAMMs, in this review, we focus on several key proteins in this family, including AMSH, AMSH-LP, BRCC36, Rpn11, and CSN5, and emphatically discuss their structural basis, diverse functions, catalytic mechanism, and current reported inhibitors targeting JAMMs. These advances set the stage for the exploitation of JAMMs as a target for the treatment of various diseases.

Citing Articles

Deubiquitinase MYSM1 drives myocardial ischemia/reperfusion injury by stabilizing STAT1 in cardiomyocytes.

Shi X, Xu J, Liu L, Zhao S, Qian Y, Fang Z Theranostics. 2025; 15(5):1606-1621.

PMID: 39897566 PMC: 11780537. DOI: 10.7150/thno.100097.

Deubiquitinase MYSM1 promotes doxorubicin-induced cardiotoxicity by mediating TRIM21-ferroptosis axis in cardiomyocytes.

Shi X, Xu J, Zhong X, Qian Y, Lin L, Fang Z Cell Commun Signal. 2024; 22(1):593.

PMID: 39695708 PMC: 11658060. DOI: 10.1186/s12964-024-01955-6.

Deubiquitinases as novel therapeutic targets for diseases.

Xian Y, Ye J, Tang Y, Zhang N, Peng C, Huang W MedComm (2020). 2024; 5(12):e70036.

PMID: 39678489 PMC: 11645450. DOI: 10.1002/mco2.70036.

Ubiquitin-Proteasome System in Periodontitis: Mechanisms and Clinical Implications.

Ma Y, Jia R, Chen S, Ma J, Yin L, Pan X Cell Prolif. 2024; 58(3):e13781.

PMID: 39626954 PMC: 11882760. DOI: 10.1111/cpr.13781.

Comparison of two UPS regulators: the 26S proteasome LID and the COP9 signalosome.

Dubiel D, Dubiel W Front Cell Dev Biol. 2024; 12:1496862.

PMID: 39600336 PMC: 11588679. DOI: 10.3389/fcell.2024.1496862.

References

Verma R, Aravind L, Oania R, McDonald W, Yates 3rd J, Koonin E . Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science. 2002; 298(5593):611-5. DOI: 10.1126/science.1075898. View

Sierra M, Wright M, Nash P . AMSH interacts with ESCRT-0 to regulate the stability and trafficking of CXCR4. J Biol Chem. 2010; 285(18):13990-4004. PMC: 2859561. DOI: 10.1074/jbc.M109.061309. View

Rabl J . BRCA1-A and BRISC: Multifunctional Molecular Machines for Ubiquitin Signaling. Biomolecules. 2020; 10(11). PMC: 7692841. DOI: 10.3390/biom10111503. View

Clague M, Urbe S . Endocytosis: the DUB version. Trends Cell Biol. 2006; 16(11):551-9. DOI: 10.1016/j.tcb.2006.09.002. View

Wei N, Serino G, Deng X . The COP9 signalosome: more than a protease. Trends Biochem Sci. 2008; 33(12):592-600. DOI: 10.1016/j.tibs.2008.09.004. View

Liu C, Powell K, Mundt K, Wu L, Carr A, Caspari T . Cop9/signalosome subunits and Pcu4 regulate ribonucleotide reductase by both checkpoint-dependent and -independent mechanisms. Genes Dev. 2003; 17(9):1130-40. PMC: 196048. DOI: 10.1101/gad.1090803. View

Wang X, Mazurkiewicz M, Hillert E, Olofsson M, Pierrou S, Hillertz P . The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells. Sci Rep. 2016; 6:26979. PMC: 4893612. DOI: 10.1038/srep26979. View

Zheng H, Gupta V, Patterson-Fortin J, Bhattacharya S, Katlinski K, Wu J . A BRISC-SHMT complex deubiquitinates IFNAR1 and regulates interferon responses. Cell Rep. 2013; 5(1):180-93. PMC: 3813903. DOI: 10.1016/j.celrep.2013.08.025. View

Mikhael J, Dingli D, Roy V, Reeder C, Buadi F, Hayman S . Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013; 88(4):360-76. DOI: 10.1016/j.mayocp.2013.01.019. View

10.

Altmann E, Erbel P, Renatus M, Schaefer M, Schlierf A, Druet A . Azaindoles as Zinc-Binding Small-Molecule Inhibitors of the JAMM Protease CSN5. Angew Chem Int Ed Engl. 2016; 56(5):1294-1297. DOI: 10.1002/anie.201608672. View

11.

Davies C, Paul L, Kim M, Das C . Structural and thermodynamic comparison of the catalytic domain of AMSH and AMSH-LP: nearly identical fold but different stability. J Mol Biol. 2011; 413(2):416-29. PMC: 3321355. DOI: 10.1016/j.jmb.2011.08.029. View

12.

Yu X, Chini C, He M, Mer G, Chen J . The BRCT domain is a phospho-protein binding domain. Science. 2003; 302(5645):639-42. DOI: 10.1126/science.1088753. View

13.

Henne W, Stenmark H, Emr S . Molecular mechanisms of the membrane sculpting ESCRT pathway. Cold Spring Harb Perspect Biol. 2013; 5(9). PMC: 3753708. DOI: 10.1101/cshperspect.a016766. View

14.

van der Linden W, Willems L, Shabaneh T, Li N, Ruben M, Florea B . Discovery of a potent and highly β1 specific proteasome inhibitor from a focused library of urea-containing peptide vinyl sulfones and peptide epoxyketones. Org Biomol Chem. 2011; 10(1):181-94. PMC: 3769973. DOI: 10.1039/c1ob06554h. View

15.

Worden E, Padovani C, Martin A . Structure of the Rpn11-Rpn8 dimer reveals mechanisms of substrate deubiquitination during proteasomal degradation. Nat Struct Mol Biol. 2014; 21(3):220-7. DOI: 10.1038/nsmb.2771. View

16.

Lingaraju G, Bunker R, Cavadini S, Hess D, Hassiepen U, Renatus M . Crystal structure of the human COP9 signalosome. Nature. 2014; 512(7513):161-5. DOI: 10.1038/nature13566. View

17.

Powers E, Morimoto R, Dillin A, Kelly J, Balch W . Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem. 2009; 78:959-91. DOI: 10.1146/annurev.biochem.052308.114844. View

18.

Matyskiela M, Lander G, Martin A . Conformational switching of the 26S proteasome enables substrate degradation. Nat Struct Mol Biol. 2013; 20(7):781-8. PMC: 3712289. DOI: 10.1038/nsmb.2616. View

19.

Wang B, Matsuoka S, Ballif B, Zhang D, Smogorzewska A, Gygi S . Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science. 2007; 316(5828):1194-8. PMC: 3573690. DOI: 10.1126/science.1139476. View

20.

Coleman K, Greenberg R . The BRCA1-RAP80 complex regulates DNA repair mechanism utilization by restricting end resection. J Biol Chem. 2011; 286(15):13669-80. PMC: 3075711. DOI: 10.1074/jbc.M110.213728. View